{
    "root": "30deba4d-85ab-64e3-e063-6394a90a085e",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Escitalopram",
    "value": "20250321",
    "ingredients": [
        {
            "name": "BUTYLATED HYDROXYANISOLE",
            "code": "REK4960K2U"
        },
        {
            "name": "BUTYLATED HYDROXYTOLUENE",
            "code": "1P9D0Z171K"
        },
        {
            "name": "SILICON DIOXIDE",
            "code": "ETJ7Z6XBU4"
        },
        {
            "name": "CROSCARMELLOSE SODIUM",
            "code": "M28OL1HH48"
        },
        {
            "name": "MAGNESIUM STEARATE",
            "code": "70097M6I30"
        },
        {
            "name": "MICROCRYSTALLINE CELLULOSE",
            "code": "OP1R32D61U"
        },
        {
            "name": "TALC",
            "code": "7SEV7J4R1U"
        },
        {
            "name": "HYPROMELLOSE 2910 (5 MPA.S)",
            "code": "R75537T0T4"
        },
        {
            "name": "POLYETHYLENE GLYCOL 400",
            "code": "B697894SGQ"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "ESCITALOPRAM OXALATE",
            "code": "5U85DBW7LO"
        }
    ],
    "indications": "escitalopram tablets indicated treatment : major depressive disorder ( mdd ) adults pediatric patients 12 years age older generalized anxiety disorder ( gad ) adults . additional pediatric information approved abbvie inc. \u2019 lexapro ( escitalopram ) tablets . however , due abbvie inc. \u2019 marketing exclusivity rights , product labeled information .",
    "contraindications": "indication population recommended mdd adults ( 2.1 ) initial : 10 mg daily recommended : 10 mg daily maximum : 20 mg daily mdd pediatric patients 12 years older ( 2.1 ) initial : 10 mg daily recommended : 10 mg daily maximum : 20 mg daily gad adults ( 2.2 ) initial : 10 mg daily recommended : 10 mg daily maximum : 20 mg daily additional benefits seen 20 mg/day dose ( 2.1 ) . administer daily , morning evening , without food ( 2.3 ) . elderly patients : recommended 10 mg daily ( 2.4 ) . hepatic impairment : recommended 10 mg daily ( 2.4 , 8.6 ) discontinuing escitalopram tablets , reduce dose gradually whenever possible ( 2.5 )",
    "warningsAndPrecautions": "escitalopram tablets usp , 10 mg white off-white , oval shaped , biconvex film-coated tablets debossed \u2018 f \u2019 one side \u2018 54 \u2019 side deep scoreline \u2018 5 \u2019 \u2018 4 \u2019 . unit dose packages 100 ( 10 x 10 ) ndc 68084-617-01 escitalopram tablets usp , 20 mg white off-white , oval shaped , biconvex film-coated tablets debossed \u2018 f \u2019 one side \u2018 56 \u2019 side deep scoreline \u2018 5 \u2019 \u2018 6 \u2019 . unit dose packages 100 ( 10 x 10 ) ndc 68084-618-01 storage handling store 20\u00b0 25\u00b0c ( 68\u00b0 77\u00b0f ) ; excursions permitted 15\u00b0 30\u00b0c ( 59\u00b0 86\u00b0f ) [ usp controlled room temperature ] . protection : blister torn broken .",
    "adverseReactions": "escitalopram tablets contraindicated patients : taking maois escitalopram tablets within 14 days stopping treatment escitalopram tablets increased risk serotonin syndrome . escitalopram tablets within 14 days stopping maoi intended treat psychiatric disorders also contraindicated [ ( 2.7 ) ( 5.2 ) ] . starting escitalopram tablets patient treated maois linezolid intravenous methylene blue also contraindicated increased risk serotonin syndrome [ ( 2.6 ) ( 5.2 ) ] . taking pimozide [ ( 7 ) ] . hypersensitivity escitalopram citalopram inactive ingredients escitalopram tablets .",
    "indications_original": "Escitalopram tablets are indicated for the treatment of:\n                  \n                     major depressive disorder (MDD) in adults and pediatric patients 12 years of age and older\n                     generalized anxiety disorder (GAD) in adults.\n                  \n                  \n                     Additional pediatric use information is approved for AbbVie Inc.\u2019s LEXAPRO (escitalopram) tablets. However, due to AbbVie Inc.\u2019s marketing exclusivity rights, this drug product is not labeled with that information.",
    "contraindications_original": "Indication and Population Recommended Dosage MDD in Adults (2.1) Initial: 10 mg once daily Recommended: 10 mg once daily Maximum: 20 mg once daily MDD in Pediatric Patients 12 years and older (2.1) Initial: 10 mg once daily Recommended: 10 mg once daily Maximum: 20 mg once daily GAD in Adults (2.2) Initial: 10 mg once daily Recommended: 10 mg once daily Maximum: 20 mg once daily No additional benefits seen at 20 mg/day dose (2.1) . Administer once daily, morning or evening, with or without food (2.3) . Elderly patients: recommended dosage is 10 mg once daily (2.4) . Hepatic impairment: recommended dosage is 10 mg once daily (2.4 , 8.6) When discontinuing escitalopram tablets, reduce dose gradually whenever possible (2.5)",
    "warningsAndPrecautions_original": "Escitalopram Tablets USP, 10 mg are white to off-white, oval shaped, biconvex film-coated tablets debossed with \u2018F\u2019 on one side and \u201854\u2019 on the other side with a deep scoreline between \u20185\u2019 and \u20184\u2019.\n  \nUnit dose packages of 100 (10 x 10) NDC 68084-617-01\n \n                  \n                     Escitalopram Tablets USP, 20 mg are white to off-white, oval shaped, biconvex film-coated tablets debossed with \u2018F\u2019 on one side and \u201856\u2019 on the other side with a deep scoreline between \u20185\u2019 and \u20186\u2019.\n  \nUnit dose packages of 100 (10 x 10) NDC 68084-618-01\n \n                  Storage and Handling\n  \n                     Store at 20\u00b0 to 25\u00b0C (68\u00b0 to 77\u00b0F); excursions permitted to 15\u00b0 to 30\u00b0C (59\u00b0 to 86\u00b0F) [see USP Controlled Room Temperature].\n \n                  \n                     FOR YOUR PROTECTION: Do not use if blister is torn or broken.",
    "adverseReactions_original": "Escitalopram tablets is contraindicated in patients:\n                  \n                     taking MAOIs with escitalopram tablets or within 14 days of stopping treatment with escitalopram tablets because of an increased risk of serotonin syndrome. The use of escitalopram tablets within 14 days of stopping an MAOI intended to treat psychiatric disorders is also contraindicated \n   [see \n    Dosage and Administration (2.7) and \n    Warnings and Precautions (5.2)]\n   . Starting escitalopram tablets in a patient who is being treated with MAOIs such as linezolid or intravenous methylene blue is also contraindicated because of an increased risk of serotonin syndrome \n   [see \n    Dosage and Administration (2.6) and \n    Warnings and Precautions (5.2)]\n   .\n  \n                     taking pimozide \n   [see \n    Drug Interactions (7)]\n   .\n  \n                     with a hypersensitivity to escitalopram or citalopram or any of the inactive ingredients in escitalopram tablets."
}